Triptolide (DrugBank: Triptolide)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 67 | 多発性嚢胞腎 | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02115659 (ClinicalTrials.gov) | April 2014 | 14/4/2014 | Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Randomized Controlled Trial of Triptolide-Containing Formulation for Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Drug: Triptolide-Containing Formulation;Drug: Placebo | Shanghai Changzheng Hospital | NULL | Recruiting | 40 Years | 75 Years | Both | 100 | Phase 3 | China |
| 2 | ChiCTR-TRC-11001282 | 2011-04-01 | 2011-04-21 | Triptolide Retards Autosomal Dominant Polycystic Kidney Disease with Proteinuria | Triptolide Retards Autosomal Dominant Polycystic Kidney Disease with Proteinuria | Autosomal dominant polycystic kidney disease;Q61.301 | Group A:Glucosidorum Tripterygll Totorum+losartan potassium ;Group B:Placebo + losartan potassium; | Shanghai Changzheng Hospital | NULL | Completed | 18 | 55 | Both | Group A:30;Group B:30; | China | |
| 3 | NCT00801268 (ClinicalTrials.gov) | November 2008 | 25/11/2008 | Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease | Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Polycystic Kidney | Drug: tripterygium wilfordii;Drug: Emodin | Zhi-Hong Liu, M.D. | NULL | Terminated | 15 Years | 70 Years | Both | 300 | N/A | China |